ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.
Led by a management team with extensive global pharma and biotech experience, ASLAN collaborates with internationally renowned experts and institutions to develop drugs – turning ground breaking research into effective therapies for those in need.
We focus on Asia prevalent tumour types, including gastric cancer, cholangiocarcinoma and breast cancer. As few effective therapies exist to treat these diseases, there is a significant unmet need globally.
Our Therapeutic Areas include:
Through our presence in Singapore, Taiwan, China and Australia, we develop drugs across the Asia Pacific region, then leverage the data for global registration, with the potential for accelerated approvals in countries where these indications are considered orphan diseases.
We have offices in Singapore, Taipei, Shanghai and Australia, and conduct regional clinical development programmes across Asia.
Founded in 2010, ASLAN has rapidly established a strong track record in oncology-focused product development. Since its founding, ASLAN has raised over $100 million in financing, formed innovative partnerships with pharmaceutical industry leaders and developed four therapeutic medicines that target cancers for which there are few effective treatments.